Arrowhead Research Corporation (ARWR) Stock Price

ARWRStock

$55.90+43.44%52W

Market Cap$7.87B

P/E—

PEG Ratio—

Div yield—

Beta1.36

ARWR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-26.08%

Price vs S&P 500 (4W)-17.41%

VGM Score54.24

P/CF (Annual)43.98x

Book Value / Share (Quarterly)$3.30

P/TBV (Annual)10.19x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)50.52%

Cash Flow / Share (Quarterly)$-0.53

Price vs S&P 500 (YTD)-27.73%

Net Profit Margin (TTM)-47.79%

EPS (TTM)$-2.24

10-Day Avg Trading Volume2.17M

EPS Excl Extra (TTM)$-2.24

Revenue Growth (5Y)56.63%

EPS (Annual)$-0.01

ROI (Annual)-0.15%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-3428.42%

Cash / Share (Quarterly)$11.32

P/E Basic Excl Extra (TTM)50.32x

Revenue Growth QoQ (YoY)171.02%

ROA (Last FY)-0.12%

Revenue Growth TTM (YoY)16.85%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-95.58%

Operating Margin (TTM)-33.82%

Cash Flow / Share (Annual)$1.16

P/B Ratio16.96x

P/B Ratio (Quarterly)24.66x

Net Income / Employee (Annual)$-2,300

EV / Revenue (TTM)13.60x

Net Interest Coverage (TTM)1.99x

ROA (TTM)-17.37%

EV / EBITDA (TTM)27.95x

EPS Incl Extra (Annual)$-0.01

Current Ratio (Annual)4.86x

Quick Ratio (Quarterly)5.81x

3-Month Avg Trading Volume2.12M

52-Week Price Return43.44%

EV / Free Cash Flow (Annual)58.02x

P/E Incl Extra (TTM)50.32x

Revenue / Employee (TTM)$941,600

Tangible BV / Share (Quarterly)$3.26

P/S Ratio (Annual)9.52x

Asset Turnover (Annual)0.60x

52-Week High$95.49

Operating Margin (5Y Avg)-3436.30%

EPS Excl Extra (Annual)$-0.01

CapEx CAGR (5Y)13.56%

Tangible BV CAGR (5Y)0.57%

26-Week Price Return-16.18%

Quick Ratio (Annual)4.81x

13-Week Price Return-24.76%

Total Debt / Equity (Annual)1.34x

Current Ratio (Quarterly)5.90x

Enterprise Value$9.10B

Revenue / Share Growth (5Y)47.98%

Asset Turnover (TTM)0.36x

Book Value / Share Growth (5Y)-5.30%

Revenue / Employee (Annual)$1,166,600

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)6.21%

Cash / Share (Annual)$6.76

3-Month Return Std Dev59.95%

Net Income / Employee (TTM)$-450,000

ROE (Last FY)-0.35%

Net Interest Coverage (Annual)-4.12x

EPS Basic Excl Extra (Annual)$-0.01

P/FCF (TTM)74.34x

Receivables Turnover (TTM)73.35x

EV / Free Cash Flow (TTM)32.79x

Total Debt / Equity (Quarterly)2.70x

EPS Incl Extra (TTM)$-2.24

Receivables Turnover (Annual)343.86x

ROI (TTM)-21.93%

P/S Ratio (TTM)11.79x

Pretax Margin (5Y Avg)-3499.99%

Revenue / Share (Annual)$6.20

Tangible BV / Share (Annual)$3.38

Price vs S&P 500 (52W)27.91%

P/E Ratio (TTM)50.32x

Year-to-Date Return-15.80%

5-Day Price Return-7.95%

EPS Normalized (Annual)$-0.01

ROA (5Y Avg)-24.96%

Net Profit Margin (Annual)-0.20%

Month-to-Date Return-14.59%

Cash Flow / Share (TTM)$-1.62

EBITD / Share (Annual)$0.91

Operating Margin (Annual)11.86%

LT Debt / Equity (Annual)1.25x

P/CF (TTM)30.00x

ROI (5Y Avg)-43.92%

P/E Excl Extra (TTM)50.32x

LT Debt / Equity (Quarterly)2.61x

EPS Basic Excl Extra (TTM)$-2.24

P/TBV (Quarterly)24.96x

P/B Ratio (Annual)10.04x

Pretax Margin (TTM)-37.65%

Book Value / Share (Annual)$3.43

Price vs S&P 500 (13W)-27.45%

Beta1.36x

P/FCF (Annual)50.33x

Revenue / Share (TTM)$4.67

ROE (TTM)-60.54%

52-Week Low$36.57

vGradeD

gGradeA

mGradeC

vgmGradeC

ARWR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$1.23	-$1.36	-10.35%(-$0.13)
Q1 2026	May 7, 2026	-$1.11	-$0.93	+15.98%(+$0.18)
Q4 2025	Feb 5, 2026	-$0.37	$0.22	+159.86%(+$0.59)
Q3 2025	Nov 25, 2025	-$0.16	-$0.18	-14.45%(-$0.02)
Q2 2025	Aug 7, 2025	-$1.10	-$1.26	-14.41%(-$0.16)

ARWR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.05

4.25

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Arrowhead Research Corporation

Arrowhead Pharmaceuticals is a biotechnology company developing genetic medicines to treat diseases caused by protein overproduction. Its pipeline spans cardiovascular, cardiometabolic, pulmonary, central nervous system, liver, muscular, and complement-mediated disease areas, with the majority of its product candidates concentrated in liver disease treatments.

ARWR Next Earnings Report

Report dateNov 24, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$1.50

Revenue estimate$60.44M

Also reporting on Nov 24, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ARWR Insider Transactions

SellAug 18, 2026
PERRY MICHAEL S
Director
Shares: 11,600Value: $1.01M
SellAug 18, 2026
OLUKOTUN ADEOYE Y
Director
Shares: 2,000Value: $173,920

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

KYMRKymera Therapeutics, Inc. Common StockBiological Products
ESIElement Solutions Inc.Industrial Chemicals
WLKWestlake CorporationIndustrial Chemicals
NEUNewMarket CorporationIndustrial Chemicals
AXTAAxalta Coating Systems Ltd.Paints & Coatings
EMNEastman Chemical CompanyPlastics & Resins
HXLHexcel CorporationPlastics & Resins
ELFe.l.f. Beauty, Inc.Cosmetics & Toiletries

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$36.57

High$95.49